{"id":"W4366817647","doi":"10.1136/rmdopen-2022-002939","title":"Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study","year":2023,"lang":"en","type":"article","venue":"RMD Open","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Global Affairs Canada; Toronto Western Hospital; University of Toronto","funders":"Genentech; Medac; Biogen; Celgene; Gilead Sciences; National Institute for Health and Care Research; Novartis Pharma; Novartis; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; Sun Pharma; GlaxoSmithKline","keywords":"Secukinumab; Medicine; Psoriatic arthritis; Placebo; Quality of life (healthcare); Internal medicine; Physical therapy; Dermatology Life Quality Index; Body mass index; Presenteeism; Disease; Absenteeism; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002199431,0.000536678,0.001330604,0.0001481081,0.0002049166,0.0004056411,0.0003281229,0.0005549116,0.001824309],"category_scores_gemma":[0.0009436093,0.0001953099,0.001392624,0.0001572445,0.0003372454,0.0004205658,0.0002115755,0.0008952321,0.0002567867],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002161179,"about_ca_system_score_gemma":0.0004255958,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002880616,"about_ca_topic_score_gemma":0.000883128,"domain_scores_codex":[0.9995086,0.0002936973,0.00003352682,0.00004141131,0.00006680435,0.00005595554],"domain_scores_gemma":[0.9993229,0.0001582935,0.0002515107,0.00004528377,0.00005890036,0.000163241],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7033836,0.03483299,0.03597215,0.001748309,0.003552435,0.000321019,0.0003058434,0.001493573,0.02976838,0.0001285944,0.00236581,0.1861272],"study_design_scores_gemma":[0.2510299,0.602495,0.1372329,0.0001361404,0.002129429,0.0005316677,0.00009948697,0.001152525,0.00269825,0.00008065349,0.002374799,0.00003922842],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940504,0.004680903,0.0002152029,0.0001651038,0.00003962295,0.0002194736,0.0001891878,0.00001706808,0.0004229535],"genre_scores_gemma":[0.995833,0.002068891,0.0004592214,0.000314055,0.00008885818,0.0002355663,0.0004771654,0.00000527195,0.0005179018],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002199431,"threshold_uncertainty_score":0.01163185,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01902606875253266,"score_gpt":0.3127914825420933,"score_spread":0.2937654137895607,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}